Atlas Trials

A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

Clinical trial NCT06331598 · WITHDRAWN

Trial details

NCT number
NCT06331598
Sponsor
Hoffmann-La Roche
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Solid Tumors
Start date
2024-11-30
Primary completion
2028-10-20
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.